Symbols / ADPT Stock $14.14 +2.32% Adaptive Biotechnologies Corporation

Healthcare • Biotechnology • United States • NMS
ADPT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NMS · United States
Market Cap 2.18B
Enterprise Value 2.17B
Income -59.50M
Sales 276.98M
FCF (ttm) 950.88K
Book/sh 1.42
Cash/sh 1.47
Employees 624
Insider 10d —
IPO Jun 27, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -52.65
PEG —
P/S 7.86
P/B 9.94
P/C —
EV/EBITDA -55.15
EV/Sales 7.82
Quick Ratio 3.10
Current Ratio 3.34
Debt/Eq 93.49
LT Debt/Eq —
EPS (ttm) -0.39
EPS next Y -0.27
EPS Growth —
Revenue Growth 51.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-02-05
ROA -6.79%
ROE -27.82%
ROIC —
Gross Margin 74.24%
Oper. Margin -17.82%
Profit Margin -21.48%
Shs Outstand 153.98M
Shs Float 118.74M
Insider Own 2.02%
Instit Own 100.73%
Short Float 7.09%
Short Ratio 4.16
Short Interest 8.55M
52W High 20.76
vs 52W High -31.89%
52W Low 7.16
vs 52W Low 97.49%
Beta 2.30
Impl. Vol. 3.13%
Rel Volume 0.44
Avg Volume 1.98M
Volume 876.14K
Target (mean) $20.57
Tgt Median $21.00
Tgt Low $19.00
Tgt High $22.00
# Analysts 7
Recom Strong_buy
Prev Close $13.82
Price $14.14
Change 2.32%
About

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$20.57
Mean price target
2. Current target
$14.14
Latest analyst target
3. DCF / Fair value
$0.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.14
Low
$19.00
High
$22.00
Mean
$20.57

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-06 main JP Morgan Overweight → Overweight $21
2026-02-06 main BTIG Buy → Buy $22
2026-01-26 main Guggenheim Buy → Buy $21
2025-11-11 main Morgan Stanley Equal-Weight → Equal-Weight $16
2025-11-06 main JP Morgan Overweight → Overweight $20
2025-11-06 main BTIG Buy → Buy $21
2025-10-22 main BTIG Buy → Buy $19
2025-10-15 main Piper Sandler Overweight → Overweight $20
2025-10-13 main JP Morgan Overweight → Overweight $17
2025-09-30 init Guggenheim — → Buy $20
2025-08-06 main JP Morgan Overweight → Overweight $14
2025-08-06 main TD Cowen Buy → Buy $15
2025-08-06 main Piper Sandler Overweight → Overweight $15
2025-06-18 init Craig-Hallum — → Buy $15
2025-05-06 main Piper Sandler Overweight → Overweight $13
2025-05-05 main Morgan Stanley Equal-Weight → Equal-Weight $9
2025-05-02 main Goldman Sachs Buy → Buy $10
2025-03-21 up Goldman Sachs Neutral → Buy $9
2025-02-20 reit Piper Sandler Overweight → Overweight $11
2025-02-13 main Scotiabank Sector Outperform → Sector Outperform $12
News
RSS: Latest ADPT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-21 RUBINSTEIN JULIAN President — 69,061 $14.55 $1,008,622
2026-04-21 RUBINSTEIN JULIAN President — 56,047 $8.46 $517,880
2026-04-16 RUBINSTEIN JULIAN President — 57,180 $14.18 $826,251
2026-04-16 RUBINSTEIN JULIAN President — 44,166 $8.46 $373,644
2026-04-13 RUBINSTEIN JULIAN President — 57,180 $12.75 $758,108
2026-04-13 RUBINSTEIN JULIAN President — 44,166 $7.27 $328,956
2026-04-08 ROBINS CHAD M Chief Executive Officer — 120,595 $14.41 $1,766,839
2026-04-08 RUBINSTEIN JULIAN President — 69,061 $13.56 $990,503
2026-04-08 RUBINSTEIN JULIAN President — 56,047 $7.27 $465,322
2026-04-08 ROBINS HARLAN S. Officer — 10,000 $14.85 $148,500
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
276.98
+54.77%
178.96
+5.10%
170.28
-8.11%
185.31
Operating Revenue
276.98
+54.77%
178.96
+5.10%
170.28
-8.11%
185.31
Cost Of Revenue
71.36
-1.00%
72.08
-4.60%
75.55
+30.47%
57.91
Reconciled Cost Of Revenue
55.23
+1.28%
54.53
-0.90%
55.02
+42.22%
38.69
Gross Profit
205.62
+92.39%
106.88
+12.83%
94.72
-25.65%
127.40
Operating Expense
262.74
+0.20%
262.22
-11.51%
296.33
-9.54%
327.58
Research And Development
93.77
-8.92%
102.95
-15.69%
122.12
-13.85%
141.76
Selling General And Administration
167.27
+6.16%
157.56
-8.66%
172.51
-6.31%
184.13
Selling And Marketing Expense
94.57
+11.58%
84.76
-4.31%
88.58
-7.35%
95.60
General And Administrative Expense
72.70
-0.14%
72.81
-13.26%
83.93
-5.19%
88.53
Other Gand A
72.70
-0.14%
72.81
-13.26%
83.93
-5.19%
88.53
Total Expenses
334.10
-0.06%
334.30
-10.11%
371.88
-3.53%
385.49
Operating Income
-57.12
+63.23%
-155.34
+22.95%
-201.61
-0.71%
-200.19
Total Operating Income As Reported
-57.12
+64.86%
-162.55
+28.40%
-227.03
-13.41%
-200.19
EBITDA
-29.85
+76.82%
-128.76
+31.97%
-189.27
-8.03%
-175.21
Normalized EBITDA
-29.85
+75.45%
-121.55
+25.81%
-163.84
+6.49%
-175.21
Reconciled Depreciation
17.83
-7.39%
19.26
-13.38%
22.23
+6.27%
20.92
EBIT
-47.68
+67.79%
-148.01
+30.02%
-211.50
-7.84%
-196.13
Total Unusual Items
0.00
+100.00%
-7.21
+71.67%
-25.43
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-7.21
+71.67%
-25.43
0.00
Special Income Charges
0.00
+100.00%
-7.21
+71.67%
-25.43
0.00
Impairment Of Capital Assets
0.00
-100.00%
7.21
-71.67%
25.43
0.00
Net Income
-59.50
+62.69%
-159.49
+29.19%
-225.25
-12.52%
-200.19
Pretax Income
-59.46
+62.75%
-159.59
+29.16%
-225.30
-12.45%
-200.37
Net Non Operating Interest Income Expense
-2.33
-179.01%
2.95
+70.65%
1.73
+1051.10%
-0.18
Interest Expense Non Operating
11.78
+1.71%
11.58
-16.09%
13.80
+225.63%
4.24
Net Interest Income
-2.33
-179.01%
2.95
+70.65%
1.73
+1051.10%
-0.18
Interest Expense
11.78
+1.71%
11.58
-16.09%
13.80
+225.63%
4.24
Interest Income Non Operating
9.44
-35.02%
14.53
-6.42%
15.53
+282.91%
4.06
Interest Income
9.44
-35.02%
14.53
-6.42%
15.53
+282.91%
4.06
Other Income Expense
—
-7.21
+71.67%
-25.43
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-59.46
+62.75%
-159.59
+29.16%
-225.30
-12.45%
-200.37
Net Income From Continuing Operation Net Minority Interest
-59.50
+62.69%
-159.49
+29.19%
-225.25
-12.52%
-200.19
Net Income From Continuing And Discontinued Operation
-59.50
+62.69%
-159.49
+29.19%
-225.25
-12.52%
-200.19
Net Income Continuous Operations
-59.46
+62.75%
-159.59
+29.16%
-225.30
-12.45%
-200.37
Minority Interests
-0.04
-140.78%
0.10
+90.74%
0.05
-69.49%
0.18
Normalized Income
-59.50
+60.93%
-152.29
+23.79%
-199.82
+0.18%
-200.19
Net Income Common Stockholders
-59.50
+62.69%
-159.49
+29.19%
-225.25
-12.52%
-200.19
Diluted EPS
-0.39
+63.89%
-1.08
+30.77%
-1.56
-11.43%
-1.40
Basic EPS
-0.39
+63.89%
-1.08
+30.77%
-1.56
-11.43%
-1.40
Basic Average Shares
151.72
+3.14%
147.10
+1.88%
144.38
+1.31%
142.52
Diluted Average Shares
151.72
+3.14%
147.10
+1.88%
144.38
+1.31%
142.52
Diluted NI Availto Com Stockholders
-59.50
+62.69%
-159.49
+29.19%
-225.25
-12.52%
-200.19
Amortization
1.70
-0.23%
1.70
+0.24%
1.70
+0.00%
1.70
Amortization Of Intangibles Income Statement
1.70
-0.23%
1.70
+0.24%
1.70
+0.00%
1.70
Depreciation Amortization Depletion Income Statement
1.70
-0.23%
1.70
+0.24%
1.70
+0.00%
1.70
Depreciation And Amortization In Income Statement
1.70
-0.23%
1.70
+0.24%
1.70
+0.00%
1.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
512.74
-4.94%
539.38
-18.42%
661.13
-22.82%
856.62
Current Assets
300.19
+5.79%
283.75
-30.82%
410.19
-27.03%
562.15
Cash Cash Equivalents And Short Term Investments
226.98
+2.11%
222.29
-35.83%
346.40
-30.47%
498.20
Cash And Cash Equivalents
70.50
+47.11%
47.92
-26.35%
65.06
-27.73%
90.03
Other Short Term Investments
156.49
-10.26%
174.37
-38.02%
281.34
-31.07%
408.17
Receivables
50.37
+20.69%
41.73
+9.91%
37.97
-5.21%
40.06
Accounts Receivable
50.37
+20.69%
41.73
+9.91%
37.97
-5.21%
40.06
Inventory
9.82
+16.35%
8.44
-41.58%
14.45
-0.03%
14.45
Prepaid Assets
—
—
—
—
Other Current Assets
13.02
+15.35%
11.29
-0.73%
11.37
+20.44%
9.44
Total Non Current Assets
212.55
-16.85%
255.62
+1.86%
250.95
-14.78%
294.47
Net PPE
74.72
-20.83%
94.38
-21.56%
120.32
-26.73%
164.21
Gross PPE
170.51
-6.42%
182.20
-5.87%
193.56
-11.44%
218.56
Accumulated Depreciation
-95.79
-9.07%
-87.82
-19.91%
-73.23
-34.75%
-54.35
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
11.11
-18.53%
13.63
-0.87%
13.76
-2.98%
14.18
Construction In Progress
1.10
-57.10%
2.57
-24.49%
3.40
-55.34%
7.62
Other Properties
85.19
-8.12%
92.72
-8.80%
101.66
-18.25%
124.36
Leases
73.11
-0.23%
73.28
-1.95%
74.73
+3.22%
72.40
Goodwill And Other Intangible Assets
120.70
-1.39%
122.40
-1.37%
124.10
-1.35%
125.80
Goodwill
118.97
+0.00%
118.97
+0.00%
118.97
+0.00%
118.97
Other Intangible Assets
1.73
-49.61%
3.42
-33.21%
5.13
-24.89%
6.83
Investments And Advances
13.23
-60.68%
33.66
0.00
0.00
Other Non Current Assets
3.90
-24.85%
5.18
-20.53%
6.52
+46.19%
4.46
Total Liabilities Net Minority Interest
287.74
-14.59%
336.89
-4.52%
352.86
-10.10%
392.52
Current Liabilities
89.92
-8.30%
98.05
+11.40%
88.02
-19.83%
109.79
Payables And Accrued Expenses
14.17
-8.14%
15.42
-5.48%
16.32
-20.44%
20.51
Payables
7.01
-5.82%
7.44
-4.33%
7.78
-6.04%
8.28
Accounts Payable
6.47
-10.98%
7.26
-5.88%
7.72
-4.52%
8.08
Current Accrued Expenses
7.16
-10.30%
7.98
-6.52%
8.54
-30.19%
12.23
Pensionand Other Post Retirement Benefit Plans Current
16.99
+7.29%
15.84
+15.73%
13.69
-14.12%
15.94
Total Tax Payable
0.54
+207.39%
0.18
+198.31%
0.06
-69.59%
0.19
Current Debt And Capital Lease Obligation
8.92
-12.88%
10.24
+9.11%
9.38
+1.67%
9.23
Current Capital Lease Obligation
8.92
-12.88%
10.24
+9.11%
9.38
+1.67%
9.23
Current Deferred Liabilities
45.19
-18.85%
55.69
+14.52%
48.63
-24.15%
64.11
Current Deferred Revenue
45.19
-18.85%
55.69
+14.52%
48.63
-24.15%
64.11
Other Current Liabilities
4.64
+436.65%
0.86
—
—
Total Non Current Liabilities Net Minority Interest
197.82
-17.17%
238.84
-9.82%
264.84
-6.33%
282.73
Long Term Debt And Capital Lease Obligation
70.23
-11.27%
79.15
-11.46%
89.39
-9.50%
98.77
Long Term Capital Lease Obligation
70.23
-11.27%
79.15
-11.46%
89.39
-9.50%
98.77
Non Current Deferred Liabilities
1.01
-96.31%
27.26
-39.15%
44.79
-23.56%
58.60
Non Current Deferred Revenue
1.01
-96.31%
27.26
-39.15%
44.79
-23.56%
58.60
Other Non Current Liabilities
126.59
-4.42%
132.43
+1.36%
130.66
+4.23%
125.36
Stockholders Equity
218.79
+7.93%
202.71
-34.27%
308.40
-33.56%
464.17
Common Stock Equity
218.79
+7.93%
202.71
-34.27%
308.40
-33.56%
464.17
Capital Stock
0.01
+7.14%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+7.14%
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
153.78
+4.06%
147.77
+1.86%
145.08
+1.38%
143.11
Ordinary Shares Number
153.78
+4.06%
147.77
+1.86%
145.08
+1.38%
143.11
Additional Paid In Capital
1,581.85
+5.01%
1,506.35
+3.71%
1,452.50
+4.70%
1,387.35
Retained Earnings
-1,363.32
-4.56%
-1,303.82
-13.94%
-1,144.33
-24.51%
-919.08
Gains Losses Not Affecting Retained Earnings
0.25
+52.41%
0.17
-22.79%
0.21
+105.22%
-4.12
Minority Interest
6.21
+2871.43%
-0.22
-85.12%
-0.12
-80.60%
-0.07
Other Equity Adjustments
0.25
+52.41%
0.17
-22.79%
0.21
+105.22%
-4.12
Total Equity Gross Minority Interest
225.00
+11.12%
202.49
-34.32%
308.28
-33.57%
464.10
Total Capitalization
218.79
+7.93%
202.71
-34.27%
308.40
-33.56%
464.17
Working Capital
210.27
+13.23%
185.70
-42.36%
322.17
-28.78%
452.36
Invested Capital
218.79
+7.93%
202.71
-34.27%
308.40
-33.56%
464.17
Total Debt
79.15
-11.45%
89.39
-9.50%
98.77
-8.55%
108.00
Capital Lease Obligations
79.15
-11.45%
89.39
-9.50%
98.77
-8.55%
108.00
Net Tangible Assets
98.09
+22.14%
80.31
-56.42%
184.30
-45.53%
338.37
Tangible Book Value
98.09
+22.14%
80.31
-56.42%
184.30
-45.53%
338.37
Available For Sale Securities
13.23
-60.68%
33.66
—
—
Investmentin Financial Assets
13.23
-60.68%
33.66
0.00
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-45.99
+51.70%
-95.21
+39.09%
-156.32
+15.02%
-183.94
Cash Flow From Continuing Operating Activities
-45.99
+51.70%
-95.21
+39.09%
-156.32
+15.02%
-183.94
Net Income From Continuing Operations
-59.46
+62.75%
-159.59
+29.16%
-225.30
-12.45%
-200.37
Depreciation Amortization Depletion
17.83
-7.39%
19.26
-13.38%
22.23
+6.27%
20.92
Depreciation
16.13
-8.08%
17.55
-14.51%
20.53
+6.82%
19.22
Amortization Cash Flow
1.70
-0.23%
1.70
+0.24%
1.70
+0.00%
1.70
Depreciation And Amortization
17.83
-7.39%
19.26
-13.38%
22.23
+6.27%
20.92
Amortization Of Intangibles
1.70
-0.23%
1.70
+0.24%
1.70
+0.00%
1.70
Other Non Cash Items
3.87
-51.83%
8.04
-35.15%
12.39
+51.25%
8.19
Stock Based Compensation
51.48
-3.97%
53.61
-14.78%
62.91
+13.39%
55.48
Provisionand Write Offof Assets
—
1.94
+39.73%
1.39
-47.42%
2.64
Asset Impairment Charge
0.56
-93.84%
9.14
-65.90%
26.82
0.00
Change In Working Capital
-57.77
-230.97%
-17.45
+62.21%
-46.18
+35.45%
-71.55
Change In Receivables
-8.65
-130.93%
-3.74
-284.25%
2.03
+108.97%
-22.65
Changes In Account Receivables
-8.65
-130.93%
-3.74
-284.25%
2.03
+108.97%
-22.65
Change In Inventory
-1.00
-118.58%
5.37
+289.29%
-2.84
-447.37%
0.82
Change In Prepaid Assets
-1.73
-2187.95%
0.08
+104.30%
-1.93
-154.35%
3.55
Change In Payables And Accrued Expense
0.67
-0.89%
0.67
+112.41%
-5.41
-176.04%
7.11
Change In Other Working Capital
-47.05
-137.22%
-19.84
+47.85%
-38.04
+37.00%
-60.38
Investing Cash Flow
37.95
-51.22%
77.79
-40.00%
129.65
+4362.89%
2.90
Cash Flow From Continuing Investing Activities
37.95
-51.22%
77.79
-40.00%
129.65
+4362.89%
2.90
Net PPE Purchase And Sale
-2.96
+19.24%
-3.66
+65.75%
-10.70
+34.57%
-16.35
Purchase Of PPE
-2.96
+19.24%
-3.66
+65.75%
-10.70
+34.57%
-16.35
Capital Expenditure
-2.96
+19.24%
-3.66
+65.75%
-10.70
+34.57%
-16.35
Net Investment Purchase And Sale
40.91
-49.78%
81.46
-41.96%
140.34
+628.91%
19.25
Purchase Of Investment
-181.71
+25.61%
-244.26
+43.14%
-429.56
-54.09%
-278.78
Sale Of Investment
222.62
-31.65%
325.71
-42.85%
569.90
+91.22%
298.03
Financing Cash Flow
30.40
+12515.35%
0.24
-89.27%
2.25
-98.30%
132.26
Cash Flow From Continuing Financing Activities
30.40
+12515.35%
0.24
-89.27%
2.25
-98.30%
132.26
Net Issuance Payments Of Debt
—
—
—
124.38
Issuance Of Debt
—
—
—
124.38
Long Term Debt Issuance
—
—
—
124.38
Net Long Term Debt Issuance
—
—
—
124.38
Net Common Stock Issuance
—
—
—
0.00
Proceeds From Stock Option Exercised
17.88
+7318.67%
0.24
-89.27%
2.25
-71.55%
7.89
Net Other Financing Charges
12.52
—
—
124.38
Changes In Cash
22.37
+230.20%
-17.18
+29.69%
-24.43
+49.91%
-48.77
Beginning Cash Position
50.82
-25.26%
68.00
-26.43%
92.43
-34.54%
141.20
End Cash Position
73.18
+44.01%
50.82
-25.26%
68.00
-26.43%
92.43
Free Cash Flow
-48.95
+50.50%
-98.88
+40.80%
-167.02
+16.61%
-200.29
Interest Paid Supplemental Data
12.64
+42.58%
8.86
-1.35%
8.98
+1718.83%
0.49
Amortization Of Securities
-2.51
+69.40%
-8.21
+10.63%
-9.18
-1339.41%
0.74
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category